Leadgene's technical strengths are rooted in our methods of protein antigen production, antibody immunization, and various downstream applications.
The fusion of splenocytes with myeloma cells to produce monoclonal antibodies (mAbs) is a common practice in many biotech institutes. While the immune system theoretically responds to any antigenic challenge, the results of fusion can sometimes be unpredictable and unstable.
Our researchers have consistently improved five procedural sections for generating hybridomas, giving us a competitive advantage. These separate sections make up a checklist and a roadmap, each with important checkpoints that must be passed before progressing. Adopting this approach to every project has led us to successfully obtain satisfactory mAb clones when our competitors failed.
Our all-in-one solution offers a comprehensive package to fulfill all our customers' research needs. For many years, we have specialized in protein and antibody production, and have provided post-production application services to our clients.
|
Multifaceted specialties for immunoassay and mAb development |
- Epitope mapping and discovery
Project-tailored assay and device suited for antibody screening and addressing binding location - Recombinant protein production
Reliable and reproducible performance in bacterial and mammalian expression systems - Immunization and titer booster
Adaptive immunizing and boosting strategies to deal with all sorts of antigen targets - Fusion subject & partner cells
Improved hybridoma cell cloning efficiencies by using a proprietary myeloma cell line - Antibody sequence analysis
Selecting mAb facilitates a smoother and swifter laboratory-industry transition
